Literature DB >> 28393232

MicroRNA-329-3p targets MAPK1 to suppress cell proliferation, migration and invasion in cervical cancer.

Wenfeng Li1, Jingjing Liang1, Zhechao Zhang1, Hongyan Lou1, Liang Zhao1, Yunsheng Xu1, Rongying Ou1.   

Abstract

Cervical cancer is the second most common gynecological cancer worldwide and remains as one of the leading causes of cancer-related death among women. Despite great progress in the treatment of cervical cancer, the 5-year overall survival rate for patients with this disease remains unsatisfactory. Over the past decade, an increasing number of studies indicate a central role for microRNAs in the initiation and progression of cervical cancer. microRNA‑329-3p (miR-329-3p) has been studied in many types of human cancer; however, the expression level, biological role and the underlying mechanism of miR-329-3p in cervical cancer has not yet been investigated. In the present study, we found that the expression levels of miR-329-3p were reduced in both cervical cancer tissues and cell lines. Low miR-329-3p expression was negatively correlated with histological grade, International Federation of Gynecology and Obstetrics (FIGO) stage, and lymph node metastasis of cervical cancer patients. In addition, upregulation of miR‑329-3p suppressed cell proliferation, migration and invasion of cervical cancer. Furthermore, MAPK1 was identified as a direct target gene of miR-329-3p. MAPK1 was significantly upregulated in cervical cancer tissues and was inversely correlated with miR-329-3p expression in the cervical cancer tissues. Silencing of MAPK1 by RNA interference mimicked the effects of miR-329-3p overexpression on cell proliferation, migration and invasion in cervical cancer. Moreover, rescue experiments showed that restoration of the expression of MAPK1 reversed the effects of miR‑329-3p overexpression in cervical cancer cells. Taken together, these findings suggest that miR-329-3p has a critical tumor-suppressive roles by directly targeting MAPK1 in cervical cancer, and it may be investigated as a novel therapeutic target for the treatment of patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28393232     DOI: 10.3892/or.2017.5555

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  24 in total

1.  Transcriptomic analysis reveals the role of a peptide derived from CRYAB on the CoCl2-induced hypoxic HL-1 cardiomyocytes.

Authors:  Xiaoshan Hu; Heng Liu; Mengmeng Li; Jingai Zhu; Zhangbin Yu
Journal:  J Thromb Thrombolysis       Date:  2021-02       Impact factor: 2.300

2.  Oncogenic Landscape of Somatic Mutations Perturbing Pan-Cancer lncRNA-ceRNA Regulation.

Authors:  Yuanfu Zhang; Peng Han; Qiuyan Guo; Yangyang Hao; Yue Qi; Mengyu Xin; Yafang Zhang; Binbin Cui; Peng Wang
Journal:  Front Cell Dev Biol       Date:  2021-05-17

Review 3.  Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer.

Authors:  Nima Hemmat; Ahad Mokhtarzadeh; Mohammad Aghazadeh; Farhad Jadidi-Niaragh; Behzad Baradaran; Hossein Bannazadeh Baghi
Journal:  Mol Biol Rep       Date:  2020-05-07       Impact factor: 2.742

Review 4.  The Progress of Methylation Regulation in Gene Expression of Cervical Cancer.

Authors:  Chunyang Feng; Junxue Dong; Weiqin Chang; Manhua Cui; Tianmin Xu
Journal:  Int J Genomics       Date:  2018-04-16       Impact factor: 2.326

5.  The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer.

Authors:  Milena Rizzo; Gabriele Berti; Francesco Russo; Monica Evangelista; Marco Pellegrini; Giuseppe Rainaldi
Journal:  Int J Genomics       Date:  2017-09-20       Impact factor: 2.326

6.  miR-329 inhibits papillary thyroid cancer progression via direct targeting WNT1.

Authors:  Liang Wu; Fulai Pei; Xiaojuan Men; Kai Wang; Deliang Ma
Journal:  Oncol Lett       Date:  2018-07-06       Impact factor: 2.967

7.  The Effect of Immunosuppressive Adjuvant Kynurenine on Type 1 Diabetes Vaccine.

Authors:  Jing Sun; Jiandong Shi; Jianfang Li; Meini Wu; Yanhan Li; Sengquan Jia; Chunli Ma; Xinyi Wang; Zhiyuan Li; Ningzhu Hu; Yunzhang Hu
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

8.  LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway.

Authors:  Xiaobo Guo; Yun Wang
Journal:  Cancer Med       Date:  2020-05-27       Impact factor: 4.452

9.  Correlation between miR-222 and uterine cancer and its prognostic value.

Authors:  Xiujuan Nie; Haili Tian
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

10.  LncRNA SNHG16 Facilitates Nasopharyngeal Carcinoma Progression by Acting as ceRNA to Sponge miR-520a-3p and Upregulate MAPK1 Expression.

Authors:  Qingwei Wu; Yingying Zhao; Runjie Shi; Tao Wang
Journal:  Cancer Manag Res       Date:  2021-05-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.